Kingworld Medicines Group Limited (KINGWORLD) filed its monthly return to Hong Kong Exchanges and Clearing Limited for the period ending 30 June 2026, showing a stable share capital structure and full compliance with Listing Rules.

The authorised share capital stayed at 10.00 billion ordinary shares with a par value of HKD 0.10, translating into HKD 1.00 billion in authorised capital—unchanged from the previous month.

Issued share capital also remained flat at 622.50 million shares, with no treasury stock on the books and no share movements—issuances, repurchases, or cancellations—recorded during June.

KINGWORLD confirmed that its public float exceeded the minimum 25 percent threshold prescribed under Main Board Rule 13.32B, ensuring ongoing compliance.

No share options, warrants, convertible securities, or other share-linked agreements were outstanding or exercised in the month, indicating no dilution risk from equity-linked instruments.

The filing was submitted on 2 July 2026 and signed by Director Zhou Xuhua, affirming adherence to all regulatory and listing requirements.